Skip to Main content Skip to Navigation
Journal articles

Combined Liver-Kidney Transplantation With Preformed Anti–human Leukocyte Antigen Donor-Specific Antibodies

Arnaud del Bello 1, 2 Olivier Thaunat 3, 4 Moglie Le Quintrec 5 Oriol Bestard 6 Antoine Durrbach 7 Peggy Perrin 8 Philippe Gatault 9, 10 Frederic Jambon 11, 12 Georges-Philippe Pageaux 5 Laura Llado Camille Besch 8 Louise Barbier 9, 13, 14 Martine Neau-Cransac 12 Jérôme Dumortier 15, 4 Nassim Kamar 1, 2 
13 FHU SUPORT - Fédération Hospitalo-universitaire SUrvival oPtimization in ORgan Transplantation
IRTOMIT - Ischémie Reperfusion en Transplantation d’Organes Mécanismes et Innovations Thérapeutiques, RESINFIT - Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques, Cellules Dendritiques, Immunomodulation et Greffes, CHU Poitiers - Centre hospitalier universitaire de Poitiers , CHU Limoges, IPPRITT - Ciblage individuel et prévention des risques de traitements immunosupresseurs et de la transplantation
Abstract : Introduction: The impact of preformed donor-specific anti–human leukocyte antigen (HLA) antibodies(pDSAs) after combined liver-kidney transplantation (CLKT) is still uncertain. Methods: We conducted a retrospective study in 8 European high-volume transplant centers and inves-tigated the outcome of 166 consecutive CLKTs, including 46 patients with pDSAs. Results : Patient survival was lower in those with pDSAs (5-year patient survival rate of 63% and 78% with orwithout pDSA, respectively;P¼0.04). The presence of pDSAs with a meanfluorescence intensity (MFI)$5000(hazard ratio 4.96; 95% confidence interval: 2.3–10.9;P<0.001) and the presence of 3 or more pDSAs (hazardratio 6.5; 95% confidence interval: 2.5–18.8;P¼0.05) were independently associated with death. The death-censored liver graft survival was similar in patients with or without pDSAs. Kidney graft survival was compa-rable in both groups. (The 1- and 5-year death-censored graft survival rates were 91.6% and 79.5%, respectively,in patients with pDSAs and 93% and 88%, respectively, in the donor-specific antibody [DSA]-negative group,P¼not significant). Despite a higher rate of kidney graft rejection in patients with pDSAs (5-year kidney graft survivalrate without rejection of 87% and 97%with or without pDSAs, respectively;P¼0.04), kidney function did notstatistically differ between both groups at 5 years post-transplantation (estimated glomerularfiltration rate 4517 vs. 5729 ml/min per 1.73 m2, respectively, in patients with and without pDSAs). Five recipients with pDSAs(11.0%) experienced an antibody-mediated kidney rejection that led to graft loss in 1 patient. Conclusion: Our results suggest that CLKT with pDSAs is associated with a lower patients’survival despitegood recipients’, liver and kidney grafts’outcome.
Document type :
Journal articles
Complete list of metadata
Contributor : Bérangère Cognata Connect in order to contact the contributor
Submitted on : Tuesday, January 11, 2022 - 10:30:48 AM
Last modification on : Wednesday, June 1, 2022 - 4:08:10 AM
Long-term archiving on: : Tuesday, April 12, 2022 - 6:43:12 PM


Publisher files allowed on an open archive


Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License



Arnaud del Bello, Olivier Thaunat, Moglie Le Quintrec, Oriol Bestard, Antoine Durrbach, et al.. Combined Liver-Kidney Transplantation With Preformed Anti–human Leukocyte Antigen Donor-Specific Antibodies. Kidney International Reports, Elsevier, 2020, ⟨10.1016/j.ekir.2020.09.018⟩. ⟨hal-03185936⟩



Record views


Files downloads